 Shares of Alimera Sciences NASDAQ:ALIM decreased 1.5 after the company reported Q2 results.Quarterly Results Earnings per share fell 628.57 year over year to 0.51, which beat the estimate of 1.44.Revenue of 10,038,000 declined by 7.53 year over year, which beat the estimate of 6,940,000.Outlook Alimera Sciences hasnt issued any earnings guidance for the time being.View more earnings on ALIMRevenue guidance hasnt been issued by the company for now.Price Action 52-week high: 9.9852-week low: 0.00Price action over last quarter: Up 12.13Company Overview Alimera Sciences Inc is a pharmaceutical company. It specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. The product portfolio of the company includes ILUVIEN, which is developed to treat diabetic macular edema. In addition, to the activities related to the development of ILUVIEN, the group is also researching the safety and effectiveness of NADPH Nicotinamide Adenine Dinucleotide Phosphate oxidase inhibitors. Geographically it operates through the region of US and also it has its presence in the international market.See more from Benzinga Recap: MYR Group Q2 Earnings Transocean: Q2 Earnings Insights PayPal Holdings: Q2 Earnings InsightsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 